Xovoltib 40mg Tablet (Afatinib)

Xovoltib 40mg Tablet (afatinib) is a targeted anticancer medicine. It is prescribed to treat non-small cell lung cancer in the adult patients who have certain mutations of epidermal growth factor receptor (EGFR). It contains afatinib as an active ingredient that belongs to the class of medications known as tyrosine kinase inhibitors. It works by inhibiting the EGFR proteins that send growth signals for the multiplication of cancer cells. By blocking this protein, the medicine slows down or stops the growth and spread of cancer cells.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed as whole with water and should not be crushed, chewed, or broken. It is usually taken on an empty stomach, at least one hour before or two hours after food. Afatinib 40mg Tablet is given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include diarrhea, skin rash, acne-like skin eruptions, dry skin, mouth sores, nail problems, itching, decreased appetite, nausea, vomiting, and nosebleeds. A few patients can undergo severe side effects, including severe skin blistering or peeling, difficulty breathing or worsening cough, liver problems, severe abdominal pain and eye pain. Most of the Afatinib 40mg Tablet side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

The medicine can harm an unborn baby, so women who are pregnant or planning pregnancy should consult with their doctor. Breastfeeding should be avoided during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Afatinib 40mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Non-Small Cell Lung Cancer

Every medicine has some side effects that resolve on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.

Some common side effects of Xovoltib 40mg Tablet (afatinib) include:
● Diarrhea
● Rash
● Dry skin
● Nausea
● Vomiting
● Loss of appetite
● Itching
● Stomatitis (inflammation of the mouth)
● Nail disorder

Take the Xovoltib 40mg Tablet (afatinib) in the dosage as prescribed by the doctor. Dosage and the duration are determined as per the patient's health condition. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken on an empty stomach. Never skip a dose or double dose.

● Sequist, L. V., Yang, J. C. H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., ... & Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology, 31(27), 3327-3334.
● Yang, Z., Hackshaw, A., Feng, Q., Fu, X., Zhang, Y., Mao, C., & Tang, J. (2017). Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis. International journal of cancer, 140(12), 2805-2819.
● Modjtahedi, H., Cho, B. C., Michel, M. C., & Solca, F. (2014). A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's archives of pharmacology, 387(6), 505-521.
● Nelson, V., Ziehr, J., Agulnik, M., & Johnson, M. (2013). Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and therapy, 135-143.
● Dungo, R. T., & Keating, G. M. (2013). Afatinib: first global approval. Drugs, 73(13), 1503-1515.